Is Neuroretinitis Associated With Multiple Sclerosis?

Affiliations

¹ Wilmer Eye Institute (NRM), Johns Hopkins University School of Medicine, Baltimore, Maryland; Neuro-Ophthalmology Unit (LNJ, TB), Warren Alpert Medical School of Brown University, Lifespan, Rhode Island Hospital, Providence, Rhode Island; Department of Ophthalmology and Visual Sciences (GPVS), Washington University in St. Louis School of Medicine, St. Louis, Missouri; and Chair, Blanton Eye Institute (AGL), Houston Methodist Hospital, Houston, Texas.

Neil R Miller et al. J Neuroophthalmol. 2022.

. 2022 Mar 1;42(1):126-130.

doi: 10.1097/WNO.0000000000001374. Epub 2021 Oct 22.

¹ Wilmer Eye Institute (NRM), Johns Hopkins University School of Medicine, Baltimore, Maryland; Neuro-Ophthalmology Unit (LNJ, TB), Warren Alpert Medical School of Brown University, Lifespan, Rhode Island Hospital, Providence, Rhode Island; Department of Ophthalmology and Visual Sciences (GPVS), Washington University in St. Louis School of Medicine, St. Louis, Missouri; and Chair, Blanton Eye Institute (AGL), Houston Methodist Hospital, Houston, Texas.

No abstract available

Conflict of interest statement

The authors report no conflicts of interest.

1. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflam. 2001;9:93–102.
1. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101–1108.
1. Dreyer RF, Hopen G, Gass JD, Smith JL. Leber's idiopathic stellate neuroretinitis. Arch Ophthalmol. 1984;102:1140–1145.
1. Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol. 2011;31:58–68.
1. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Wall M. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944–949.